aTYR PHARMA (ATYR) Depreciation & Amortization (CF) (2014 - 2026)

aTYR PHARMA (ATYR) has 13 years of Depreciation & Amortization (CF) data on file, last reported at $162000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 2.99% year-over-year to $162000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $695000.0 (changed 0.29% YoY) and the FY2025 annual result came in at $700000.0, down 1.13% from the prior year.
• Depreciation & Amortization (CF) slipped to $162000.0 in Q1 2026, from $202000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $202000.0 in Q4 2025 to a low of $39000.0 in Q4 2022.
• A 5-year average of $141294.1 and a median of $166000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) sank 63.89% — and 2023, when it soared 369.23%.
• Tracing ATYR's Depreciation & Amortization (CF) over 5 years: stood at $39000.0 in 2022, then soared by 369.23% to $183000.0 in 2023, then fell by 4.37% to $175000.0 in 2024, then rose by 15.43% to $202000.0 in 2025, then retreated by 19.8% to $162000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $162000.0 (Q1 2026), $202000.0 (Q4 2025), and $165000.0 (Q3 2025), per Business Quant data.